Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMZJPOB)

Drug Name
MDDR 287569 Drug Info
Synonyms N-[1-[3-(4-Methylpiperazin-1-ylsulfonyl)propyl]piperidin-4-ylmethyl]-2,3-dihydro-1,4-benzodioxin-5-carboxamide
Indication
Disease Entry ICD 11 Status REF
Urinary incontinence MF50.2 Investigative [1] , [2]
Cross-matching ID
TTD Drug ID
DMZJPOB

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 4 receptor (HTR4) TT07C3Y 5HT4R_HUMAN Modulator [1] , [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
5-HT 4 receptor (HTR4) DTT HTR4 5.776 4.945 5.062 4.828
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Urinary incontinence
ICD Disease Classification MF50.2
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 4 receptor (HTR4) DTT HTR4 6.16E-01 -0.03 -0.24
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF Prostate Cancer Clinical Trials Consortium. Invest New Drugs. 2012 April; 30(2): 749-757.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015